|
|
|
|
|
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination With Cisplatin in Subjects With Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma
SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma
100 Clinical Results associated with RaND Bioscience, Inc.
0 Patents (Medical) associated with RaND Bioscience, Inc.
100 Deals associated with RaND Bioscience, Inc.
100 Translational Medicine associated with RaND Bioscience, Inc.